Spero Therapeutics, Inc.

SPRO · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$7,382-$1,700-$13,866-$20,888
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$1,048$714$1,556$1,503
Change in WC$22,886-$16,985$8,035-$4,284
Other Non-Cash$870$278$273$268
Operating Cash Flow$17,422-$17,693-$4,002-$23,401
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$0$0$0$0
Forex Effect$0$0$0$0
Net Chg. in Cash$17,422-$17,693-$4,002-$23,401
Supplemental Information
Beg. Cash$31,194$48,887$52,889$76,290
End Cash$48,616$31,194$48,887$52,889
Free Cash Flow$17,422-$17,693-$4,002-$23,401
Spero Therapeutics, Inc. (SPRO) Financial Statements & Key Stats | AlphaPilot